BRD4/CK2-IN-1

• UNSPSC Description:

  BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC50s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC)[1]

• Target Antigen:

  Apoptosis; Autophagy; Casein Kinase; Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/brd4-ck2-in-1.html

• Solubility:

  DMSO : 20 mg/mL (ultrasonic;warming;adjust pH to 3 with HCl;heat to 60°C)

• Smiles:

  O=C1C2=C(OC)C=C(OC)C=C2N=C(C3=CC=C(OCC(NC4=CC(Cl)=C(N5CCN(C)CC5)C=C4)=O)C=C3)N1

• Molecular Weight:

  564.03

• References & Citations:

  [1] Zhang J, et al. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy. J Med Chem. 2021;64(24):18025-18053.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2756851-99-5